Need Help?
Copied to clipboard!

Classical Hodgkin Lymphoma: Atlas of Blood Cancer Genomes

cHL encompasses distinct histologic subtypes within an immune-rich tumor microenvironment, yet their biological differences remain incompletely understood. Here, we integrated clinical features, gene expression profiles and immune deconvolution with survival to identify determinants of outcome in 117 patients. Interestingly, we found that each cHL type had characteristic patterns: lymphocyte-rich cHL was enriched for B-cell and antigen-presenting cell programs with higher memory B-cell fractions, nodular sclerosis demonstrated a higher proportion of activated dendritic cells, lymphocytedepleted cases were relatively immune-depleted with increased M2 macrophages, and mixed cellularity showed intermediate features. Notably, although cHL subtypes did not differ significantly in overall survival (OS), classification of patients based on the combination of EBV status and age did significantly stratify OS, with EBV+ patients ≥60 years old showing the poorest survival (p<0.05). IDO1 was found to be upregulated in EBV+ tumors and significantly correlated with CD274 expression, suggesting the potential efficacy of a targeted immunotherapy strategy in these patients. The results of this study paint a comprehensive portrait of cHL subtypes and support evaluation of IDO1 inhibitors and other checkpoint blockade strategies specifically in EBV+ cHL patients.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000001951 Illumina NovaSeq X 25
EGAD50000001952 Illumina NovaSeq X 45
EGAD50000001953 Illumina NovaSeq X 34
EGAD50000001954 Illumina NovaSeq X 21
EGAD50000001955 Illumina NovaSeq X 49
EGAD50000001956 Illumina NovaSeq X 5
EGAD50000001957 Illumina NovaSeq X 25
EGAD50000001958 Illumina NovaSeq X 7